SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
oleh: Seonju Yi, Young June Choe, Jia Kim, Yoo-Yeon Kim, Ryu Kyung Kim, Eun Jung Jang, Do Sang Lim, Hye Ryeon Byeon, Sangwon Lee, Eonjoo Park, Seung-Jin Kim, Young-Joon Park
| Format: | Article |
|---|---|
| Diterbitkan: | Centers for Disease Control and Prevention 2022-03-01 |
Deskripsi
We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).